Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Contineum Therapeutics typically reports earnings before the market opens, meaning Day 0 captures the first full trading session reaction while Day +1 reflects follow-through momentum.

Historical price behavior around earnings shows moderate volatility with an average absolute Day 0 move of 4.41% and Day +1 move of 3.91%. The stock has demonstrated a slight positive bias, with five of the past eight earnings releases resulting in gains on Day 0. The most significant reaction came in Q2 2026, when shares surged 9.53% on earnings day following the positive surprise, though this was followed by a modest 1.65% pullback the next session.

The trading ranges tell a more volatile story, with Day 0 intraday swings averaging 8.82% and Day +1 ranges averaging 9.54%, indicating substantial intraday volatility even when the net directional move is modest. The largest single-day range occurred in Q1 2026 at 9.96%, coinciding with a 7.07% decline despite a significant earnings beat. This pattern suggests that investors react not just to the headline numbers but to forward guidance, clinical trial updates, and cash burn commentary—factors that can override a simple earnings beat.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 22.64% for the upcoming earnings release, significantly higher than the historical average Day 0 move of 4.41% and even exceeding the average Day 0 intraday range of 8.82%. This elevated implied volatility suggests options traders are anticipating a much larger reaction than historical patterns would indicate, possibly reflecting heightened uncertainty around clinical trial updates or strategic direction following the recent workforce reduction and research program streamlining.

Part 3: What Analysts Are Saying

Analysts maintain a cautiously optimistic stance on Contineum Therapeutics, with a consensus rating of 4.13 (Buy) and an average price target of $22.00. The current breakdown shows 4 Strong Buy ratings, 1 Moderate Buy, and 3 Hold ratings, with no sell recommendations. However, sentiment has deteriorated over the past month, with the average recommendation declining from 4.38 as one Strong Buy rating was downgraded.

The average price target of $22.00 implies 140% upside from the current price of $9.16, with estimates ranging from a low of $14.00 to a high of $30.00. This wide range reflects divergent views on the company's clinical pipeline value and execution risk. The high target of $30.00 suggests some analysts see substantial value in the PIPE-791 IPF program and the Johnson & Johnson partnership, while the low target of $14.00 indicates more conservative assumptions about clinical success probabilities and timeline to commercialization.

The recent sentiment deterioration appears tied to the stock's technical weakness and concerns about the company's strategic pivot. While analysts appreciate management's focus on capital discipline and the promising PROPEL-IPF enrollment momentum, the departure of key research personnel and streamlining of discovery programs has introduced execution uncertainty. The consensus remains constructive on the long-term opportunity, but near-term catalysts beyond steady clinical trial progress appear limited, contributing to the more cautious tone.

Part 4: Technical Picture

The Barchart Technical Opinion presents a strongly bearish picture heading into earnings, with the signal at 100% Sell compared to 80% Sell one week ago and just 8% Sell one month ago. This dramatic deterioration reflects accelerating downside momentum as the stock has broken below key support levels.

Timeframe Analysis:

• Short-term (100% Sell): Strong sell signal indicates severe near-term downward pressure with no technical support
• Medium-term (100% Sell): Bearish reading confirms the intermediate-term trend has fully broken down
• Long-term (100% Sell): Sell signal across all timeframes suggests a comprehensive technical breakdown with no bullish divergences

Strong and Strengthening trend characteristics indicate the bearish momentum is not only severe but intensifying, creating a challenging technical backdrop for the earnings release. The uniformly negative signals across all timeframes suggest limited technical support to cushion any disappointment.

The stock is trading at $9.16, positioned above its 5-day moving average of $8.60 and 10-day moving average of $8.22, but below all longer-term moving averages including the 20-day ($9.91), 50-day ($12.97), 100-day ($13.54), and 200-day ($13.57). This configuration indicates a short-term bounce within a broader downtrend, with the stock trading 32.5% below its 50-day moving average. The 52-week range of $6.73 to $17.79 shows the stock is closer to its lows, with the recent low of $6.73 representing potential support if selling accelerates. The technical setup is decidedly cautionary heading into earnings, with the stock lacking meaningful overhead resistance until the $10-$11 zone but also showing little in the way of established support structures. Any positive surprise would need to be substantial to reverse the deteriorating technical picture, while a disappointment could accelerate the move toward the 52-week low.